Clinical efficacy and tolerability of new non-freon aerosol of troventol in asthma
The study was designed to assess clinical efficacy and tolerability of new non-freon aerosol of troventol. The study involved 20 patients (4 males and 16 females) with intermittent or mild persistent stable asthma aged 22 to 67 yrs, the average age, 44.3 ± 11.1 (М ± SD). Anticholinergic effect of troventol was assessed under a single inhalation of the drug (the acute test) which was the 1-st stage of the study, and after long-term (4 wks) treatment which was the 2-nd stage. Clinical efficacy was evaluated by Borg's scoring of cough and dyspnoea, lung and heart auscultation, need in short-acting beta-2-agonists. The acute test included the metacholine challenge test before and 3 hrs after inhalation of 80 mcg of troventol or placebo. The long-term treatment stage included the metacholine challenge test before and in 4 weeks of daily inhalations of 160 mcg of troventol. As a result, the new non-freon aerosol of troventol demonstrated distinct brochodilating and anticholinergic effects which significantly differed from placebo in patients with intermittent or mild persistent stable asthma. Being administered for a long period (4 wks) the drug improved cough and dyspnoea and reduced the need in short-acting beta-agonists while bronchial airflow parameters did not change considerably. There were no adverse events of the therapy during the study.